Division of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Section of Vascular Surgery, Department of Cardiac Surgery, Wuhan Asia Heart Hospital, Wuhan, Hubei, China.
Ann Vasc Surg. 2022 Feb;79:114-121. doi: 10.1016/j.avsg.2021.08.006. Epub 2021 Oct 10.
Coronavirus disease 2019 (COVID-19) has become a global pandemic which may compromise the management of vascular emergencies. An uncompromised treatment for ruptured abdominal aortic aneurysm (rAAA) during such a health crisis represents a challenge. This study aimed to demonstrate the treatment outcomes of rAAA and the perioperative prevention of cross-infection under the COVID-19 pandemic.
In cases of rAAA during the pandemic, a perioperative workflow was applied to expedite coronavirus testing and avoid pre-operative delay, combined with a strategy for preventing cross-infection. Data of rAAA treated in 11 vascular centers between January-March 2020 collected retrospectively were compared to the corresponding period in 2018 and 2019.
Eight, 12, and 14 rAAA patients were treated in 11 centers in January-March 2018, 2019, and 2020, respectively. An increased portion were treated at local hospitals with a comparable outcome compared with large centers in Guangzhou. With EVAR-first strategy, 85.7% patients with rAAA in 2020 underwent endovascular repair, similar to that in 2018 and 2019. The surgical outcomes during the pandemic were not inferior to that in 2018 and 2019. The average length of ICU stay was 1.8 ± 3.4 days in 2020, tending to be shorter than that in 2018 and 2019, whereas the length of hospital stay was similar among 3 years. The in-hospital mortality of 2018, 2019, and 2020 was 37.5%, 25.0%, and 14.3%, respectively. Three patients undergoing emergent surgeries were suspected of COVID-19, though turned out to be negative after surgery.
Our experience for emergency management of rAAA and infection prevention for healthcare providers is effective in optimizing emergent surgical outcomes during the COVID-19 pandemic.
2019 年冠状病毒病(COVID-19)已成为全球大流行疾病,可能会影响血管急症的处理。在这种健康危机期间,破裂的腹主动脉瘤(rAAA)的治疗仍需不受影响,这是一个挑战。本研究旨在展示 COVID-19 大流行期间 rAAA 的治疗结果以及围手术期交叉感染的预防。
在大流行期间 rAAA 患者中,应用围手术期工作流程来加快冠状病毒检测,避免术前延误,并结合预防交叉感染的策略。回顾性收集 2020 年 1 月至 3 月期间 11 个血管中心治疗的 rAAA 数据,并与 2018 年和 2019 年同期进行比较。
2018 年 1 月至 3 月、2019 年 1 月至 3 月和 2020 年 1 月至 3 月,分别有 8、12 和 14 例 rAAA 患者在 11 个中心接受治疗。与广州的大型中心相比,在当地医院接受治疗的患者比例增加,其结果相似。2020 年,85.7%的 rAAA 患者采用 EVAR 优先策略行腔内修复术,与 2018 年和 2019 年相似。大流行期间的手术结果并不逊于 2018 年和 2019 年。2020 年 ICU 住院时间平均为 1.8±3.4 天,有缩短趋势,而 3 年的住院时间相似。2018 年、2019 年和 2020 年的院内死亡率分别为 37.5%、25.0%和 14.3%。3 例急诊手术患者疑似 COVID-19,但术后均为阴性。
我们在 rAAA 急救管理和医疗保健提供者感染预防方面的经验在优化 COVID-19 大流行期间的紧急手术结果方面是有效的。